Polo-like kinase1 (PLK1) belongs to the family of serine/ threonine kinases and plays an important role in centrosome maturation, bipolar spindle formation, and cytokinesis during mitosis. We found in this study that PLK1 was aberrantly highly expressed in a variety of human leukemia cell lines (n ¼ 20), as well as, freshly isolated leukemia cells from individuals with acute myelogenous leukemia (n ¼ 50) and acute lymphoblastic leukemia (n ¼ 15) compared with bone marrow mononuclear cells from healthy volunteers (n ¼ 13) (acute myelogenous leukemia, P ¼ 0.016; acute lymphoblastic leukemia, P ¼ 0.008), as measured by real-time RT-PCR. Downregulation of PLK1 by a small interfering RNA in NB4 acute myelogenous leukemia cells inhibited their proliferation. GW843682X is a novel selective PLK1 inhibitor. The compound-induced growth inhibition, caused accumulation of cells in the G2/M phase of the cell cycle and mediated apoptosis of human leukemia cells. Pre-treatment of cells with the caspase inhibitor Z-VAD-FMK attenuated the action of GW843682X in leukemia cells, indicating the involvement of the caspase pathway in the PLK1 inhibitor-mediated apoptosis. Furthermore, we found that the PLK1 inhibitor synergistically potentiated the growth inhibition and apoptosis of leukemia cells when combined with tubulindepolymerizing agent vincristine. Taken together, targeting PLK1 may be a promising treatment strategy for individuals with leukemia.
Introduction
The polo-like kinases (PLKs) belong to the family of mitotic serine/threonine kineses and consist of four members: PLK1, PLK2/Snk, PLK3/Fnk/Prk, and PLK4/Sak, which contain a highly conserved N-terminal kinase domain and one or two C-terminal regions of similarity termed polo box domain. 1, 2 Among them, the best characterized member is PLK1. Reactive expression of PLK1 is low during the G0/G1 phase, begins to rise in the S phase and peaks during the M phase of the cell cycle in normal cells. 3, 4 PLK1 plays important roles in various events during mitosis including regulation of centrosome maturation, 5 bipolar spindle formation, 6 and cytokinesis. 7 In addition, PLK1 regulates progression of the cell cycle through activation of the protein phosphatase cdc25C. PLK1 phosphorylates cdc25C at Ser198, leading to translocation of cdc25C to nucleus, where it activates CDK1-Cyclin B1 and triggers mitotic entry into mitosis. 8 Recent studies have found that PLK1 has aberrantly increased expression in a variety of solid tumors including colon and breast cancers. [9] [10] [11] Elevated expression of PLK1 has been associated with an adverse prognosis in colon, as well as nonsmall cell lung cancer. 9, 10, 12 Forced expression of either wildtype or kinase-inactive PLK1 caused multi-nucleation, 7 a feature characteristics of chromosomal instability found in cancer cells. Furthermore, forced expression of PLK1 caused transformation of NIH 3T3 fibroblasts. 13 These observations suggested that PLK1 might be a promising molecular target in solid tumors. However, little is known about PLK1 in malignant and normal hematopoietic cells.
This study found that human acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL) cells aberrantly expressed PLK1 compared with normal bone marrow mononuclear cells. Exposure of AML and ALL cells to GW843682X, RNA isolation and reverse transcription-polymerase chain reaction RNA isolation and cDNA preparation were performed as described earlier. 19 We measured expression of 18S for normalization as described earlier. 19 Real-time PCR was carried out by using Power SYBR Green PCR Master Mix (Applied Biosystems, Warrington, UK) as described earlier. 19 Primers for polymerase chain reaction (PCR) are shown in Table 1 . PCR conditions for all genes were as follows: 95 1C initial activation for 10 min followed by 45 cycles at 95 1C for 15 s and 60 1C for 30 s, and fluorescence determination at the melting temperature of the product for 20 s on an ABI PRISM 7000 (Applied Biosystems).
Quantitative assessment of PLK1
To quantify PLK1 target transcripts, we first validated a standard curve constructed with serial dilutions of known starting copy number (10 -4 -10 0 ) of cDNA from the MT-1 cell line, as described earlier. 16 The standard curve was obtained by a correlation of standard concentration versus the threshold cycle value (Ct). A strong linear relationship between the Ct and the PLK1 copy number (r40.99) was found over a range of at least five orders of magnitude with a PCR efficiency value of 90%. Similar results were obtained with a standard curve of the endogenous control 18S (data not shown). The PLK1 transcript values obtained by RT-PCR were normalized with respect to the number of 18S transcripts and were expressed as PLK1 copy numbers every 10 3 copies of 18S (PLK1/18S Â 1000). Polo-like kinase 1 mRNA expression þ hematopoietic stem cells from a healthy volunteer and subjected to western blot analysis. The membranes were sequentially probed with anti-PLK1 and GAPDH antibodies. The band intensity was quantified with ImageJ software (Wayne Rasband, NIH) and expressed in arbitrary units as a ratio of levels of PLK1 to those of GAPDH to correct for variation in the amount of protein. The relative expression of PLK1 protein was also normalized to a mean value (value ¼ 1) for MT-1 cells. PLK1, polo-like kinase1.
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Cell-cycle analysis by flow cytometry
Cell-cycle analysis was performed on leukemia cells incubated with GW843682X (0.1-1 mM) for 2 days at 5 Â 10 5 cells/ml in 12-well plates (Flow Laboratories, Irvine, CA, USA), as described earlier. 20 
Measurement of p-cdc25C at Ser198 by flow cytometry
Anti-p-cdc25C (Ser198, Cell Signaling Technology, Beverly, MA, USA) was used to measure the levels of the phosphorylated forms of cdc25C protein in freshly isolated leukemia cells. This experiment was performed using flow cytometry.
Quantification of p-Bcl-xl-expressing cells by flow cytometry
Cells were stained with anti-p-Ser (clone 4A4, Millipore, Billerica, MA, USA) and -Bcl-xl (Cell Signaling Technology) antibodies. R-phycoerythrin (PE)-or fluorescein isothiocyannate (FITC)-conjugated secondary antibody was used. P-Ser and Bclxl-expressing cells were quantified by flow cytometry, as described earlier. 21 
Apoptosis assays
The ability of GW843682X to induce apoptosis of leukemia cells was measured by annexin V-FITC apoptosis detection kit according to the manufacturer's instructions (Pharmingen, Inc., San Diego, CA, USA).
Immunoblotting
Immunoblotting was performed as described earlier. 22 Anti-PLK1 (Abcam, Cambridge, MA, USA), poly ADP-ribose polymerase (PARP) (Cell Signaling Technology), -cleaved PARP (Cell Signaling Technology), -cleaved caspase 3 (Cell Signaling Technology), and glyceraldehyde 3 phosphate dehydrogenase (GAPDH) (Abcam) antibodies were used. The band intensity was quantified with ImageJ software (Wayne Rasband, NIH) and expressed in arbitrary units as a ratio of levels of PLK1 to those of GAPDH to correct for variation in the amount of protein. The relative expression of PLK1 protein was also normalized to a mean value (value ¼ 1) for MT-1 cells.
Small interfering RNA
Control small interfering RNA (siRNA) and an siRNA against PLK1 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Transfections
NB4 cells were transiently transfected with either control or PLK1 siRNA by Amaxa electroporator Nucleofector II (Wako Pure Chemical Industries, Ltd., Osaka, Japan), using the Nucleofector Kit V (Wako Pure Chemical Industries, Ltd., Osaka, Japan) (program X-001). The preliminary experiments using the green fluorescence protein-expressing vector found that efficacy of transfection with this program was approximately 70% with approximately 80% cell viability, as measured by FACS and annexin V staining, respectively (figure not shown).
Data analysis
The combination index (CI) for growth inhibition elicited by GW843682X and vincristine in leukemia cells was calculated using the median effect method (Calcusyn Software available from Biosoft, Cambridge, UK), as described earlier. 23 CI values o1 indicate synergy, a CI ¼ 1 indicates an additive effect, and a CI 41 indicates antagonism between the two agents.
Statistical analysis
The non-parametric Mann-Whitney U-test was performed to assess the difference of levels of PLK1 between each group by using PRISM statistical analysis software (GraphPad Software, Table 2 ) and CD34 þ hematopoietic stem cells from healthy volunteers (n ¼ 3) were cultured in methylcellulose medium in the presence of various concentrations of GW843682X (0.25-1 mM). After 14 days, colonies were counted. Results represent the mean±s.d. of triplicate plates. (e) GW843682X inhibited the phosphorylation of cdc25C (Ser198) in leukemia cells. Freshly isolated leukemia cells (case nos. 1,2, 4, and 6, Table 2) were exposed to either GW843682X (1 mM) or control diluent. After 1 h, the p-cdc25C (Ser198)-expressing population was measured by FACScan. GW, GW842682X. (f) GW843682X dephosphorylated Bcl-xl in leukemia cells. PALL-2 and BALM-27 cells were exposed to GW843682X (0.5 or 1 mM). After 24 h, cells were incubated with anti-Bcl-xl and anti-p-Ser antibodies. Subsequently, cells were incubated with either FITC-or PE-conjugated secondary antibodies and were subjected to FACS. Upper right quadrants, population of Bcl-xl and p-Ser double positive cells. PLK1, polo-like kinase1; siRNA, small interfering RNA. . Expression levels are displayed as a ratio between the PLK1 and a reference gene (18S) to correct for variation in the amounts of RNA. The non-parametric Mann-Whitney U-test was performed to assess the difference of levels of PLK1 between each group. PBMCs, peripheral blood mononuclear cells; BMMCs, bone marrow mononuclear cells; AML, acute myelogenous leukemia; ALL, acute lymphoblastic leukemia; ATL, adult T-cell leukemia; PLK1, polo-like kinase1.
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Inc., San Diego, CA. USA). Statistical analysis was performed to assess the difference between two groups under multiple conditions by one-way analysis of variance followed by Boneferroni's multiple comparison tests.
Results
Leukemia cells aberrantly express PLK1
To verify the implication of PLK1 in leukemogenesis, expression of PLK1 was examined in a panel of leukemia cell lines by realtime PCR. Expression levels were expressed as a ratio between PLK1 and the reference gene 18S to correct for variation in the amounts of RNA. The relative target gene expression was also normalized to a mean value (value ¼ 1) for MT-1 adult T-cell leukemia cells (calibrator) as described earlier. 16 Each of the normalized target values was divided by the calibrator normalized target value to generate the final relative expression levels. PLK1 was constitutively expressed in a variety of human leukemia cells ( Figure 1a ). These cell lines also expressed PLK1 at the protein level ( Figure 1b ). On the other hand, PLK1 was not detectable in CD34
þ hematopoietic stem cells from a healthy volunteer (Figure 1b ).
We next explored whether freshly isolated leukemia cells expressed PLK1. AML cells (n ¼ 50) highly expressed PLK1 compared with peripheral blood mononuclear cells (n ¼ 12) and BMMCs (n ¼ 13) from healthy volunteers (mean±s.e., 14±2.3 in AML, 0.2 ± 0.1 in peripheral blood mononuclear cells; Po0.0001, 3.9±1.1 in BMMCs; P ¼ 0.018) ( Figure 2 ). ALL cells (n ¼ 15) also highly expressed PLK1 compared to BMMCs (mean±s.e., 26±7.2 in ALL; P ¼ 0.008). In addition, six out of seven acute type of adult T-cell leukemia cells had elevated levels of PLK1 (Figure 2 ).
Inhibition of PLK1 by GW842682X-induced growth arrest of leukemia cells Abbreviations: BM, bone marrow; F, female; FAB, French-American-British (leukemia classification); M, male; PB, peripheral blood; Pt, patient; WBC, white blood cells. Leukemia cells were freshly isolated from peripheral blood or bone marrow of patients and were cultured in methylcellulose medium in the presence of cytokines with/without various concentrations of GW843682X (0.25-1 mM). After 12 days, colonies were counted. Concentration of GW843682X that induced 50% inhibition of colony formation (IC 50 ) was calculated from the dose-response curves.
Polo-like kinase 1 and leukemia T Ikezoe et al positive acute lymphoblastic leukemia-2 (PALL-2) Ph þ ALL cells (Figures 3a and b) . We also found that inhibition of PLK1 by siRNA slowed the proliferation of NB4 cells compared with the control siRNA transfected cells (Figure 3c ). We next examined the anti-proliferative effects of GW843682X on freshly isolated leukemia cells from patients using a clonogenic assay. PLK1 transcripts were detectable in all cases, as measured by realtime PCR (Table 2; Figure 3d ). Exposure of these cells to various concentrations of GW843682X (0.25-1 mM) decreased colony forming ability with IC 50 s of o1 mM in all cases (Table 2) . Of note, GW843682X was active against relapsed Ph þ ALL cells (case no. 4) obtained after conventional chemotherapy including imatinib followed by allogeneic hematopoietic stem cell transplantation ( Figure 3d ; Table 2 ). Another relapsed sample of Ph þ ALL (case no. 6) obtained after treatment with imatinib was also sensitive to GW843682X (Figure 3d ; Table 2 ). On the other hand, GW843682X (0.25-1 mM) did not affect colony forming ability of CD34 þ hematopoietic stem cells from bone marrow of healthy volunteers (n ¼ 3; Figure 3d ).
The cdc25C protein phosphatase is a substrate of PLK1 and regulates mitotic entry. 8 Freshly isolated leukemia cells constitutively expressed p-cdc25C (Ser198) and exposure of these cells to GW843682X (1 mM) for 1 h deceased the p-PLK1 positive population of cells (Figure 3e ).
Inhibition of PLK1 dephosphorylated Bcl-xl in leukemia cells
Recent studies found that PLK1 phosphorylated anti-apoptotic protein Bcl-xl at 13 Ser/Thr residues, and regulated apoptosis of fibrosarcoma cells. 23 We therefore examined whether GW843682X dephosphorylated Bcl-xl in leukemia cells. PALL-2 and BALM-27 cells constitutively expressed p-Bcl-xl ( Figure 3f ). As expected, exposure of these cells to GW843682X (0.5-1 mM) decreased the number of cells expressing p-Bcl-xl (Figure 3f ).
Inhibition of PLK1 caused accumulation of cells in the G2/M phase of the cell cycle
We next explored the mechanism by which GX843682X inhibited the proliferation of leukemia cells. Exposure of leukemia cells (PALL-2, BALM-18, -27, and MOLM13) to pre-G1, 35% G0/G1, 0% S, 25% G2/M, 39% 
GW843682X-induced apoptosis in leukemia cells
The presence of apoptotic cells was assessed by measuring annexin V staining in BALM27 and MOLM13 cells treated with GW843682X (Figure 5a ). Exposure of these cells to GW843682X (0.1-1 mM) for 24 h induced apoptosis in a doseand time-dependent manner (Figure 5a ). For example, exposure to either 0.5 or 1 mM GW843682X induced either 60 or 80% of BALM27 cells, respectively, to become apoptotic at 24 h (Figure 5a ). Forty-six percentage of MOLM13 cells were apoptotic under the same condition (Figure 5a ).
The ability of GW843682X to induce apoptosis of leukemia cells was further explored by western blot analysis. Exposure of leukemia cells (PALL-2, BALM-27, -18, and MOLM13) to GW843682X (0.1-1 mM) for 24 h induced cleavage of caspase 3 and PARP, a feature characteristic of apoptosis, in a dosedependent manner (Figure 5b) . Notably, when BALM-27 cells were pre-treated with the pan-caspase inhibitor Z-VAD-FMS (50 mM, for 1 h), GW843682X-induced growth inhibition and apoptosis were blunted (Figures 5c and d ). These observations suggest that the action of GW843682X in BALM-27 cells was, at least in part, caspase dependent.
Inhibition of PLK1 potentiated the anti-proliferative activity of vincristine
We examined the ability of GW843682X to enhance the antiproliferative effects of the conventional anti-leukemia drug, vincristine. BALM-27 and MOLM13 leukemic cells were cultured with various concentrations of GW843682X (0.06-1 mM) and/or vincristine (0.06-2.5 nM) for 24 h; and proliferation was measured by MTT assay (Figure 6a ). GW843682X potentiated the anti-proliferative activity of vincristine in these cells. For example, effect of GW843682X (0.25 mM) on the proliferation of BALM-27 cells was negligible. Vincristine (2.5 nM) alone inhibited MTT activity by approximately 30% (Figure 6a ). When cells were exposed to both compounds in combination, proliferation was inhibited by 450% (Figure 6a ). Isobologram analysis found that CI values o1 at a fixed ratio of GX843682X versus vincristine, indicating a highly synergistic interaction (Figure 6a ). Synergistic growth inhibition mediated by combination of GW843682X and vincristine was also shown in freshly isolated leukemia cells (case nos. 10 and 11, Figure 6b ). In addition, GW843682X (0.25 mM) significantly enhanced vincristine-induced apoptosis of leukemia cells as measured by both annexin V staining and detection of the cleaved form of PARP (Figures 6c and d) .
Furthermore, we explored the mechanism by which GW843682X enhanced the action of vincristine in leukemia cells. Exposure of BALM-27 or MOLM13 cells to vincristine (1.25-2.5 mM, 24 h) accumulated the cells in the G2/M phase of the cell cycle and increased levels of PLK1 (Figures 6e and g ). One the other hand, RAD001, an analog of rapamycine, induced accumulation of cells in the G0/G1 phase of the cell cycle and decreased the levels of PLK 1 protein in these cells (Figures 6f and h) . As expected, the drug interaction of GW843682X and RAD001 was antagonistic (Figure 6i) .
Discussion
This study explored the level of PLK1 in hematological malignancies, as well as, normal hematopoietic cells. Both AML and ALL cells possessed significantly higher levels of PLK1 than normal peripheral blood mononuclear cells and BMMCs (Figures 1 and 2 ), suggesting that PLK1 may be involved in leukemogenesis and can be a promising molecular target for treatment of these diseases. In fact, downregulation of PLK1 by the siRNA inhibited the proliferation of NB4 AML cells (Figure 3c ). GW843682X is a novel ATP-competitive inhibitor of PLK1 with at least a 100-fold selectivity for PLK1 (IC 50 value, 2.2 nM) over other kinases including Aurora A, CDK1, and CDK2.
14 GW843682X was active in vitro against a variety of solid tumors including lung, colon, breast, and prostate cancers. 14 This study found that it effectively inhibited the proliferation of a variety of leukemia cells, caused accumulation of the leukemic cells in the G2/M phase of the cell cycle, and induced apoptosis associated with activation of caspase 3 (Figures 3-5) . Recently, other investigators have also shown that GW843682X-induced growth arrest of U937 AML cells in association with accumulation of these cells in the G2/M phase of the cell cycle.
24
GW843682X also inhibits the kinase activity of PLK3 with IC 50 value of 9.1 nM.
14 PLK3 was downregulated in lung as well as head and neck carcinoma, and forced expression of PLK3 in these cells slowed their proliferation, suggesting that PLK3 acted as tumor suppressor gene in these cells. 25, 26 Contrary to our expectation, leukemia cells including NB4 and eosinophilic leukemia (EOL)-1 cells constitutively expressed PLK3; however, depletion of PLK3 in NB4 and EOL-1 cells by an siRNA significantly stimulated their proliferation (data not shown). These observations suggested that PLK3 negatively regulated the proliferation of leukemia cells. GW843682X-induced growth 1-1 mM) . After 24 h, cells were harvested and proteins were extracted and subjected to western blot analysis. The membrane was sequentially probed with anti-cleaved PARP, -cleaved caspase 3, -caspase 3, and -GAPDH antibodies. (c) Pan-caspase inhibitor blunted GW843682X-mediated apoptosis. Left panel: western blot analysis. BALM-27 cells were cultured with either Z-VAD-FMS (50 mM) or control diluent (0.1% dimethyl sulfoxide (DMSO)) for 1 h then exposed to GW843682X (0.5 mM). After 24 h, cells were harvested and proteins were extracted and subjected to western blot analysis. The membrane was sequentially probed with antibodies direct against cleaved PARP, cleaved caspase 3, caspase 3, and GAPDH. Results represent one of the three experiments performed independently. Right panel: MTT assay. BALM-27 cells were cultured with either Z-VAD-FMS (50 mM) or control diluent (0.1% DMSO) for 1 h then exposed to various concentrations of GW842682X (0.25-0.5 mM). After 24 h, the proliferation of BALM-27 cells was measured by MTT assay. Experiments were repeated twice in triplicate plate. GW, GW843682X; Z-VAD, Z-VAD-FMS.
Polo-like kinase 1 and leukemia T Ikezoe et al inhibition of leukemia cells was probably independent of its action against PLK3. GW843682X effectively inhibited clonogenic growth of freshly isolated leukemia cells from patients including those who were refractory to conventional therapies (Table 2 , case nos. 2-4, 5,6). Notably, GW843682X was active against primary Ph-positive (Ph þ ) ALL cells who had relapsed after conventional chemotherapy combined with imatinib (Table 2 , case no. s 4 and 6). In addition, GW843682X profoundly inhibited the proliferation and induced apoptosis of Ph þ PALL-2 ALL cells. In general, prognosis of patients with Ph þ ALL is very poor; our results suggest that a clinical study with this PLK1 inhibitor should be tried against this extremely difficult disease to treat.
MOLM13 and AML cells from case nos 7-9 possessed the internal tandem duplications (ITDs) of the juxtamembrane domain of FMS-like tyrosine kinase 3 (FLT3/ITD, data not shown). FLT3-ITD is found in approximately 30% of AML 
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pre-G1=8% G0/G1=55% S=26% G2/M=11% pre-G1=10% G0/G1=60% S=16% G2/M=14% pre-G1=20% G0/G1=45% S=11% G2/M=24% pre-G1=39% G0/G1=18% S=6% G2/M=37% PLK-1 There appears to be some correlation between levels of PLK1 proteins and sensitivity of cells to GW843682X. For example, levels of PLK1 protein in NB4, HL60, and PALL-2 were relatively high and these cells were sensitive to GW843682X-mediated growth inhibition. On the other hand, MOLM13 and EOL-1 leukemia as well as Raji, Ramos, and Daudi Burkitt lymphoma/ leukemia cells expressed low levels of PLK1 proteins and IC 50 s of these cells were relatively high (Figures 1 and 3) . However, it is not true in all cases. The activity of PLK1 may not be the only factor that determines the sensitivity of cells to GW843682X-mediated growth inhibition. One of the key factors may be p53, which was shown to be inhibited by PLK1. 28 Inhibition of PLK1 by GW843682X might activate p53, resulting in growth inhibition and apoptosis of leukemia cells. In fact, PALL-2 cells, which possess wild-type p53 gene, were most sensitive to GW843682X (Figure 3b) . Similarly, our earlier studies found that PALL-2 cells were most sensitive to the growth inhibition mediated by the Aurora kinase inhibitors, that upregulated levels of p53 in these cells. 16, 29 The status of p53 gene might be one of the key factors that determine the sensitivity of leukemia cells to growth inhibition and apoptosis caused by the inhibitor of mitotic kinases.
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Interestingly, GW843682X synergistically potentiated the ability of the tubulin-depolymerizing agent vincristine to induce growth arrest and apoptosis of leukemia cells (Figure 6 ).
Vincristine binds to the b-tubulin subunit of the a/b-tubulin heterodimer, and inhibits polymerization of microtubules, resulting in failure of mitosis. 30 GW843682X disrupted spindle formation and aborted mitoses in lung adenocarcinoma cells.
14 Thus, both agents target mitosis but their mode of action differs between them, which could explain why they synergistically inhibit leukemic cell growth. Similarly, we have recently shown that AZD1152, the inhibitor of Aurora B kinase, synergistically enhanced the action of vincristine in leukemia cells in vitro as well as in vivo.
24 AZD1152 also disrupts various events in mitosis. The combination of the tubulin-depolymerizing agent and the inhibitor of mitotic kinases may be a promising treatment strategy for cancer. The combination of the PLK1 inhibitor and tubulin-depolymerizing agent, such as docetaxel and paclitaxel in solid tumors should be explored in future experiments.
This study found that vincristine increased levels of PLK1 in BALM-27 cells in parallel with accumulation of cells in the G2/ M phase of the cell cycle (Figure 6d ), and synergized with GW843682X to inhibit the growth of these cells. On the other hand, the drug interaction of GW843682X and RAD001, which decreased the levels of PLK1 in association with accumulation of cells in the G0/G1 phase of the cell cycle, was antagonistic (Figures 6e and f) . These observations suggested that the inhibitor of PLK1 probably acted in the G2/M phase-specific manner in leukemia cells. The combined administration of the PLK1 inhibitor and the agent, which induces G2/M cell-cycle arrest, should be recommended. In addition, the levels of PLK1 in leukemia cells might predict the sensitivity of cells to the inhibitor of PLK1. -G1=5%  G0/G1=56%  S=28%  G2/M=11%   pre-G1=6%  G0/G1=66%  S=21%  G2/M=7%   pre-G1=7%  G0/G1=67%  S=18%  G2/M=8%   pre-G1=4%  G0/G1=71%  S=17%  G2/M=8%   pre-G1=6%  G0/G1=68%  S=19%  G2/M=7%   800 
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Taken together, PLK1 is a promising molecular target for treatment of individuals with hematological malignancies including AML and ALL. Clinical studies are warranted to evaluate the efficacy, as well as, safety of this class of compounds in patients. Combined administration of the PLK1 inhibitor and other chemotherapeutic agents such as vincristine, should be further investigated.
